Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

Sponsor
Mesoblast, Inc. (Industry)
Overall Status
No longer available
CT.gov ID
NCT00759018
Collaborator
(none)
27

Study Details

Study Description

Brief Summary

This protocol allows for the treatment of pediatric patients, male and female, between the ages of 2 months and 17 years. Patients must have failed steroid treatment for Grade B-D acute GVHD.

Condition or Disease Intervention/Treatment Phase
  • Biological: remestemcel-L

Detailed Description

For the treatment of pediatric patients who have failed to respond to steroid treatment for acute graft-versus-host disease (GVHD). Failing steroid treatment for acute GVHD is defined as any Grade B-D (IBMTR grading) of acute GVHD that is not improving after at least 3 days of methylprednisolone (≥ 1 mg/kg/day) or equivalent.

Patients will be treated with Prochymal twice per week at a dose of 2 x 10^6 hematopoietic stem cells (hMSC)/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.

Study Design

Study Type:
Expanded Access
Official Title:
Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    2 Months to 17 Years
    Sexes Eligible for Study:
    All
    Inclusion criteria:
    • Patients must sign an informed consent form (ICF) before any protocol-related procedures, including any pre-treatment procedures, are performed.

    • Since patients being treated with Prochymal® under this protocol are under 18, a parental signature of informed consent will be required.

    • Patients must be 2 months to 17 years of age, inclusive.

    • Patients must have failed to respond to steroid treatment for Grades B-D acute GVHD • Failure to respond to steroid treatment for acute GVHD is defined as any Grade B-D acute GVHD that is not improving after at least 3 days of methylprednisolone (≥1 milligram per kilogram per day [mg/kg/day]) or equivalent.

    Exclusion criteria:
    • Patient must not have a known allergy to bovine or porcine products.

    • Patient must not have received a transplant for a solid tumor disease.

    • Patients must not have evidence of a pulmonary infiltrate or diffuse alveolar hemorrhage and must be unlikely to require more than 2 liters (L) of oxygen via face mask or an estimated fraction of inspired oxygen (FiO2) of 28% via other delivery methods in order to sustain an O2 saturation of 92% during the next 3 days.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Phoenix Children's Hospital Phoenix Arizona United States 85016
    2 Children's Hospital of Orange County Orange California United States 92868
    3 UCSF San Francisco California United States 94143
    4 Children's National Washington District of Columbia United States 20010
    5 Nemours Children's Clinic Jacksonville Florida United States 32207
    6 University of Miami Miami Florida United States 33136
    7 Childrens Memorial Chicago Illinois United States 60614
    8 James Witcomb Riley Hosptial for Children Indianapolis Indiana United States 46202
    9 LSU Health Science Center/Children's Hospital New Orleans Louisiana United States 70118
    10 Wayne State University/Childrens' Hospital Detroit Michigan United States 48201
    11 Children's Mercy Hospital Kansas City Missouri United States 64108
    12 Washington University School of Medicine Saint Louis Missouri United States 63110
    13 Hackensack University Medical Center Hackensack New Jersey United States 07601
    14 Columbia Medical Center New York New York United States 10032
    15 Memorial Sloan-Kettering Cancer Center New York New York United States 10065
    16 Levine Children's Hospital Charlotte North Carolina United States 28232
    17 Duke University Medical Center Durham North Carolina United States 27710
    18 Doernbecher Children's Hospital (OHSU) Portland Oregon United States 97239
    19 Medical University of South Carolina Charleston South Carolina United States 29425
    20 Vanderbilt Children's Hospital Nashville Tennessee United States 37232
    21 Texas Childrens Hospital Houston Texas United States 77030
    22 Methodist Childrens Hospital of South Texas San Antonio Texas United States 78229
    23 Massey Cancer Center Richmond Virginia United States 23298
    24 Medical College of Wisconsin Milwaukee Wisconsin United States 53226
    25 Alberta Children's Hospital Calgary Alberta Canada T3B 6A8
    26 Montreal Children's Hospital Montreal Quebec Canada H3H1P3
    27 CHU Sainte-Justine Montreal Quebec Canada H3T1C5

    Sponsors and Collaborators

    • Mesoblast, Inc.

    Investigators

    • Study Director: Mahboob Rahman, Mesoblast, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mesoblast, Inc.
    ClinicalTrials.gov Identifier:
    NCT00759018
    Other Study ID Numbers:
    • 275
    First Posted:
    Sep 25, 2008
    Last Update Posted:
    Mar 9, 2020
    Last Verified:
    Mar 1, 2020
    Keywords provided by Mesoblast, Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 9, 2020